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Abstract. Well-designed medical decision support system (DSS) have been shown 
to improve health care quality. However, before they can be used in real clinical 
situations, these systems must be extensively tested, to ensure that they conform to 
the clinical guidelines (CG) on which they are based. Existing methods cannot be 
used for the systematic testing of all possible test cases.
We describe here a new exhaustive dynamic verification method. In this method, 
the DSS is considered to be a black box, and the Quinlan C4.5 algorithm is used to 
build a decision tree from an  exhaustive set of DSS input vectors and outputs. 
This method was successfully used for the testing of a medical DSS relating to 
chronic diseases: the ASTI critiquing module for type 2 diabetes.
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Introduction
Clinical Guidelines (CG) are useful for physicians [1]. However, guidelines printed on 
paper are difficult to use efficiently during medical consultation [2]. This has led to the 
development of decision support systems (DSS) based on the CG [3]. The ASTI project 
in France provides an example of such a system. This DSS aims to improve therapeutic 
care for patients with chronic diseases, by helping physicians to take into account the 
recommendations expressed in CG [4]. ASTI includes a critiquing module — a rule-
based system composed of  a  knowledge  base and an inference engine  [5,  6].  This 
module  is  automatically activated when the physician writes  a  drug prescription;  it 
compares the treatment proposed by the physician with that recommended by the CG, 
and issues an alert if they differ. ASTI has been applied to several chronic diseases, 
including type 2 diabetes.
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Before their use in real clinical situations, DSS such as ASTI must be extensively 
tested to ensure their medical validity. Errors may be encountered at various levels: in 
the knowledge base, in the inference engine or in the system specifications. Few papers 
on the testing of medical DSS have been published, although knowledge-based system 
verification  has  been  widely  studied  outside  the  medical  domain.  Preece  [7,  8] 
distinguishes between two types of verification method. Static methods do not require 
the DSS to be run. They involve the inspection of the knowledge base by an expert, or 
checking for syntactic errors, logical errors (e.g. unsatisfiable conditions) or semantic 
errors (e.g. a male patient being pregnant) in the knowledge base [9]. These methods 
may identify errors, but cannot ensure the total absence of errors [7, 10].
Dynamic methods involve the running of the DSS with a test base. The test base 
may be written manually,  or using automatic  methods aiming to identify the “most 
relevant”  test  cases  [10,  11].  The  intervention  of  a  human  expert  is  required  to 
determine whether the responses of the DSS are satisfactory. These methods therefore 
cannot be used for the systematic testing of all possible test cases, as there are generally 
too many such cases for manual review by an expert.
We aimed to check the conformity of the ASTI critiquing module to the CG used to 
design  it  — the  French  CG for  type  2  diabetes  [12].  We present  a  new dynamic 
verification  method  for  ``rebuilding''  the  knowledge  contained  in  the  CG from  an 
exhaustive set of test cases, using machine learning techniques to construct a decision 
tree. We applied this method to the ASTI critiquing module for type 2 diabetes, and 
present the results of a comparison, by an expert, of the generated decision tree with the 
original CG. Finally, we discuss the potential value of such a method and possibilities 
of applying this method to other DSS.
1  Methods
We  propose  a  general  verification  method  with  three  steps:  (1)  generation  of  an 
exhaustive  set  of  possible  input  vectors  for  the  DSS,  and  running  of  the  DSS  to 
determine the output for each input vector, (2) extraction of knowledge from the set of 
(input vector,  output result) pairs by applying learning or generalization algorithms, 
and (3) comparison, by an expert, of the knowledge extracted in step 2 with the original 
source of knowledge (here, the CG).
1.1  Generating Input Vectors and Outputs
It is possible to generate an exhaustive (or almost exhaustive) set of input vectors by 
considering a set of variables expressing the various elements of input for the DSS, and 
generating all possible combinations of the variables' values. Continuous variables (e.g. 
glycosylated haemoglobin) are limited to a few values, corresponding, for example, to 
the threshold values expressed in the CG. Finally, the output associated with each input 
vector is obtained by running the DSS.
1.2  Building the Decision Tree
A decision tree is built from the input vectors and the associated outputs, using C4.5 
[13], a reference algorithm in machine learning. Pruning must be disabled, to ensure 
0% error in the tree. Factorization rules are applied to reduce the size of the tree: (1) if 
all the children of a given node include the same element of a recommendation (e.g. a 
recommended drug treatment), this element of information can be included in the node 
and removed from its children, (2) if a variable can take several values leading to the 
same  recommendations,  the  largest  set  of  such  values  can  be  grouped  together  as 
“<other>”.
1.3  Comparing the Decision Tree with Clinical Guidelines
Finally, the decision tree is compared with the CG by experts. These experts should be 
medical experts briefly trained in the evaluation method and the reading of the decision 
tree. The experts must check that the treatments recommended by the tree conform to 
the CG, and should check the CG to ensure that none of the recommendations included 
in the CG are missing from the tree.
2  Results
The general method presented above was applied to the ASTI critiquing module for 
type 2 diabetes.
2.1  Generating Input Vectors
The  inputs  of  the  ASTI  critiquing  module  are  related  to  (a)  the  patient's  clinical 
condition, (b) the patient's  treatment history, (c) the new treatment proposed by the 
physician,  and (d) efficiency and the tolerance of the current  treatment.  For type 2 
diabetes, these inputs correspond to the variables shown in Table 1. Doses were taken 
into account, using the following rule: if the treatment proposed is the same as the 
current  treatment,  the  dose  is  understood  to  be  modified:  reduced  if  the  problem 
identified  was  poor  tolerance,  and  increased  if  the  problem  identified  was  low 
efficiency. A few rules were used to eliminate unrealistic combinations. For example, if 
the current treatment is diet, there cannot be drug intolerance.
Combinations of the values given in Table 1 generated an almost exhaustive set of 
input vectors. Only cases in which the patient had more than one drug intolerance, and 
cases  involving  quadritherapies  (which  are  never  recommended  by  the  CG)  were 
excluded. This approach yielded 147,680 input vectors.
2.2  Building the Decision Tree
The data were initially processed so that the list of valid treatments was used as the 
classifying  variable,  rather  than  the  critiquing  module’s  output  (i.e. conform,  not 
optimal or non conform). The decision tree was then built using the C4.5 algorithm. 
Before  the  factorization  rules  described  in  the  methods  section  were  applied,  the 
decision tree  included  87 nodes.  After  the application  of  these rules,  the final  tree 
included only 60 nodes (see Figure 1).
For a  patient  with a  BMI of  25 kg/m² and an HbA1c level  of  7%, with a  current 
treatment of diet plus metformin shown to be inefficient, the decision tree recommends 
a first-line treatment of diet + metformin (with a higher dose of metformin as the
Variable Definition Retained values
Diabetes discovery Was diabetes discovered at an early or 
late stage ?
Early, late
BMI Body mass index <= 27 kg/m², > 27 kg/m²
HbA1c Glycosylated hemoglobin levels <= 6.5%, > 6.5% (*)
Current type of treatment The type of the treatment currently 
administered
No treatment, diet only, 
monotherapy, bitherapy, tritherapy, 
single daily insulin treatment, 
fractioned insulin treatment
Current treatment Treatment currently administered 19 possible values, e.g.: no 
treatment, diet, diet+metformin
Problem The medical problem preventing the 
continuation of current treatment
Low efficiency, poor tolerance
Efficiency Level of efficiency of the current 
treatment (meaningful only if the 
problem is low efficiency)
Partial, null
Poorly tolerated drug The drug in the current treatment 
responsible for intolerance (meaningful 
only if the problem is poor tolerance)
Metformin, sulfonamide, glinide, 
alpha-glucosidase inhibitors, 
glitazone, very slow-acting insulin, 
delayed-action insulin
Proposed treatment The new treatment proposed by the 
physician, which may or may not 
conform to the CG
(As for current treatment)
Table 1:  The list of variables considered for type 2 diabetes, and the values retained. (*) Only two values  
were considered, as ASTI makes use of treatment efficiency to determine whether the treatment should be 
strengthened.
recommended treatment is the same as the current treatment, see section 3.1), diet + 
glinide,  diet  +  sulfonamide,  diet  +  metformin  +  glinide  or  diet  +  metformin  + 
sulfonamide, and a second-line treatment of diet + glinide + alphaglucosidaseinhibitors 
(AGI), diet + metformin + AGI, diet + sulfonamide + AGI, diet + metformin + glinide, 
diet + metformin + sulfonamide or diet + metformin + glitazone.
For a patient with a BMI of 29 kg/m² and an HbA1c level of 6.8%, with a current 
treatment of diet plus metformin, and who does not tolerate the metformin, the decision 
tree recommends a first-line treatment of diet + AGI, and a second-line treatment of 
diet + glinide or diet + sulfonamide. However, decreasing the dose of the metformin is 
not recommended.
2.3  Comparing the Decision Tree with Clinical Guidelines
We asked  two  physicians  to  compare  the  decision  tree  with  the  original  CG.  The 
experts found the decision tree to be easily readable, although one of them was at first 
confused by the use of only two levels of treatment intention on the tree. The experts 
searched the tree for the therapeutic recommendations expressed in the CG, and found 
that none of them was missing. They also ensured that the various branches of the tree 
lead to the same prescription that the CG. Consequently, the experts considered the tree 
to conform to the CG.
+--problem = low efficiency: diet+metformin OR
|   |                       (diet+glinide+AGI OR
|   |                        diet+metformin+AGI OR
|   |                        diet+sulfonamide+AGI)
|   +--BMI <= 27: diet+glinide OR
|   |             diet+metformin+glinide OR
|   |             diet+metformin+sulfonamide OR
|   |             diet+sulfonamide OR
|   |            (diet+metformin+glitazone)
|   +--BMI >  27: diet+metformin+glitazone OR
|                (diet+glinide OR
|                 diet+metformin+glinide OR
|                 diet+metformin+sulfonamide OR
|                 diet+sulfonamide)
+--problem = poor tolerance:
    +--BMI <= 27: diet+glinide OR diet+sulfonamide
    |   +--poorly_tolerated_drug = metformin: diet+AGI
    |   +--poorly_tolerated_drug = <other>  : diet+metformin
    +--BMI >  27: (diet+glinide OR diet+sulfonamide)
        +--poorly_tolerated_drug = metformin: diet+AGI
        +--poorly_tolerated_drug = <other>  : diet+metformin
Figure 1:  Part of the decision tree generated, limited to patients currently treated by monotherapy and with 
HbA1c levels > 6.5%. Treatments in brackets are recommended as second-line treatments only. Treatments 
on non-terminal nodes apply to all the child nodes. AGI = alpha glucosidase inhibitors.
3  Discussion and conclusion
The verification method proposed made it possible to test the ASTI critiquing module 
for type 2 diabetes in an almost systematic manner. It also gives an overview of the 
DSS reasoning. The knowledge extracted from the DSS was represented using rules 
and decision lists as alternatives to decision trees. Rules were more verbose than the 
tree. The decision list was a little more concise, but it was easier to compare the tree 
with the textual CG, due to the tree-like sectioning of the CG. Other algorithms could 
be used,  e.g. for controlling the tree's optimality. We tried to insert errors by deleting 
arbitrary  rules  in  ASTI's  knowledge  base;  these  errors  were  clearly  visible  in  the 
decision tree and were found by the experts.
The  method  proposed  here  has  several  advantages.  First,  it  permits  almost 
systematic testing. ASTI was preliminary tested with a hand-written test based on 796 
input vectors.  The method used here involved about 150,000 input vectors — three 
orders of magnitude greater than initially tested. Second, this method tests not only the 
DSS knowledge base, but also the inference engine. The decision tree obtained is not a 
simple conversion of the rule-based knowledge base into a decision tree. Indeed, the 
inference engine of the ASTI critiquing module includes several  hard-coded generic 
rules: e.g. if the patient tolerated a drug poorly in the past, it should not be prescribed 
again, unless its dose is decreased. The decision tree took into account the knowledge 
base, but also these generic rules, including any possible bugs in the inference engine.
Finally, the method proposed considers the DSS as a black box, and thus makes no 
assumptions about its internal functioning. This method could therefore be applied to 
many other DSS, independently from the DSS reasoning method: rule-based system, 
hard-coded rules, decision tree, neural network, or any other algorithm. All DSS based 
on a human-readable source of knowledge, such as a CG, are eligible (by opposition to 
e.g. a DSS using the k-nearest neighbours algorithm), which includes most of medical 
knowledge based DSS. To apply our testing method, one should first identify the DSS 
inputs, generate an almost exhaustive set of input vectors, and run the DSS for each of 
them.  Then,  one should extract  knowledge from the input  vectors  and output  data, 
using C4.5 or another learning algorithm. Finally, one should ask a human expert to 
compare the extracted knowledge to the knowledge that was used to build the DSS.
Three problems might be encountered when applying this method. First, it can be 
difficult to generate an almost exhaustive set of the DSS's input vectors, in particular 
when the number of variables is very high, e.g. for hypertension CG, or when there are 
many  continuous  variables.  However  medical  recommendations  usually  define 
threshold values that allow to discretize continuous variable easily, as we have done for 
diabetes type 2. Second, it might be impossible to generate in a reasonable time the 
outputs  for  all  input  vectors  (DSS too  slow or  too  many vectors).  Third,  learning 
algorithms might be unadapted to the knowledge used by the DSS. For example, rule 
conditions such as ``if  the patient has two or more risk factors from a given list...''  
cannot  be  learnt  by  C4.5.  To  solve  this  problem,  one  can  use  more  sophisticated 
learning algorithms, e.g. based on description logic, or derive input variables from the 
other variables, e.g. the number of risk factors could be added as an input variable.
In  conclusion,  the  ASTI  critiquing  module  for  type  2  diabetes  was  almost 
exhaustively  tested  in  this  study,  using  an  original  black-box  dynamic  verification 
method. This method appears generic and therefore applicable to other medical DSS.
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